PROs and cons of short-term ADT.
Headline: In RTOG 0815, short-term ADT resulted in a transiently worse decline in sexual patient-reported outcomes without impacting other patient reported outcomes.
The Study: The use of short-term ADT for men with prostate cancer often involves a complex risk/benefit analysis, and toxicity has an important influence on the decision of many men. In RTOG 0815, men with intermediate risk prostate cancer received dose escalated radiation (mostly EBRT 79.4/44) with or without 6 months of total androgen suppression (LHRH agonist/antagonist + antiandrogen). We’ll learn more about the oncologic outcomes later today at the plenary session. Here is a look at multiple instruments used to evaluate the effects of ADT on patient reported toxicity. To no surprise, men who received ADT had a greater decline in sexual PROs compared to baseline compared to those who didn’t, but they typically recovered by 12 months. Also to no surprise, there was no difference in urinary or bowel PROs between arms, and they again recovered to baseline by 6 months. Finally, there were no differences in patient reported fatigue or sleep dysfunction.
TBL: You're now armed with the cons part of your pro and cons discussion of adding ADT to radiation for intermediate risk prostate cancer. | Movsas, ASTRO 2021